Above the 40 (November 7, 2018) – Exclamation Points for the End of Oversold Trading Conditions

AT40 = 40.5% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 37.4% of stocks are trading above their respective 200DMAs VIX = 16.4 Short-term Trading Call: bullish Commentary Financial markets made their votes very clear after the U.S. 2018 midterm election. via GIPHY Apparently, today’s rally in the S&P 500 … Read more

Above the 40 (August 17, 2018) – Another Picture-Perfect Rebound Ends Stretched Conditions

AT40 = 55.4% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 56.7% of stocks are trading above their respective 200DMAs VIX = 12.6 Short-term Trading Call: neutral Commentary The recovery from the February swoon has been full of nearly predictable bounces: whether it was oversold trading conditions or support at … Read more

Above the 40 (October 6, 2017) – Stock Market Lift-Off

AT40 = 73.8% of stocks are trading above their respective 40-day moving averages (DMAs) – overbought day #7 AT200 = 59.7% of stocks are trading above their respective 200DMAs VIX = 9.7 Short-term Trading Call: bullish Commentary This is what a lift-off for an extended overbought rally looks like. The S&P 500 (SPY) followed its … Read more

Above the 40 (September 11, 2017) – The S&P 500 Hits Fresh All-Time High On Tension Relief

AT40 = 53.0% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 51.1% of stocks are trading above their respective 200DMAs VIX = 10.7 (down 11.5%) Short-term Trading Call: neutral (see below for caveats) Commentary I had no idea that the previous tensions in the stock market fully priced in the … Read more

Allergan Signals Higher Prices Potentially Ahead for Teva Pharmaceuticals

Teva Pharmaceuticals (TEVA) lost 24% last Thursday after reporting disappointing earnings. From the Seeking Alpha transcript of the conference call: “All of us at Teva understand the frustration and disappointment our shareholders are feeling… In our U.S. Generics business, we experienced accelerated price erosion and decreased volume, mainly due to customer consolidation, greater competition as … Read more

Mylan’s Other EpiPen Classification Issue and Unresolved Overhang

(This is an excerpt from an article I originally published on Seeking Alpha on October 19, 2016. Click here to read the entire piece.) Mylan (MYL) is down 13% (and as much as 17%) since I argued the company was “out of tune” with an angry chorus that promised to place a lot of short-term … Read more

Hate the Game, Not the Player? – Mylan Is Out of Tune Amid An Angry Chorus

(This is an excerpt from an article I originally published on Seeking Alpha on August 29, 2016. Click here to read the entire piece.) This is the message actress Sarah Jessica Parker posted on Instagram Thursday, August 25, 2016 to join a chorus of protest and complaint about the extremely high cost of the EpiPen® … Read more

T2108 Update (September 2, 2016) – Still Waiting for Volatility’s Moment

(T2108 measures the percentage of stocks trading above their respective 40-day moving averages [DMAs]. It helps to identify extremes in market sentiment that are likely to reverse. To learn more about it, see my T2108 Resource Page. You can follow real-time T2108 commentary on twitter using the #T2108 hashtag. T2108-related trades and other trades are … Read more